选择性细胞因子抑制剂BNZ-1有效治疗揭示T-LGL白血病对细胞因子的依赖性
这是一项在需要治疗的伴血细胞减少(贫血或中性粒细胞减少)的T细胞大颗粒淋巴细胞白血病(T-LGLL)患者中开展的BNZ-1 1/2期试验。BNZ-1在20%的患者中诱导临床部分缓解,毒性轻微,未达到最大耐受剂量;T-LGL白血病细胞在治疗第2天即出现显著凋亡增加,且贯穿治疗全程与基线有统计学差异(P < .005)。
要点
- BNZ-1在T-LGLL患者中诱导20%的临床部分缓解,毒性轻微,未达到最大耐受剂量。
- T-LGL白血病细胞在BNZ-1治疗第2天即出现显著凋亡增加,包括临床无缓解者,P < .005。
- 首次在人体中证明T-LGL白血病细胞依赖IL-15,抑制IL-15具有治疗效应。
核心结论
- 首次在人体中证明T-LGL白血病细胞依赖IL-15,使用BNZ-1抑制IL-15在T-LGLL患者中显示治疗效应。
研究设计与样本
- 在需要治疗的伴血细胞减少(贫血或中性粒细胞减少)的T-LGLL患者中开展BNZ-1的1/2期试验。
- 临床缓解依据东部肿瘤协作组5998 T-LGLL试验的缓解标准,通过血液学参数(血细胞减少改善)评估。
- 试验注册于www.clinicaltrials.gov,注册号为#NCT03239392。
主要发现
- BNZ-1在20%的T-LGLL患者中诱导临床部分缓解,毒性轻微,未达到最大耐受剂量。
- T-LGL白血病细胞在BNZ-1治疗第2天即出现显著凋亡增加,包括临床无缓解者,且贯穿治疗全程与基线有统计学差异(P < .005)。
关键数值与推荐
- 临床部分缓解率:20%(T-LGLL患者)。
- 凋亡变化与基线比较:P < .005(T-LGL白血病细胞,BNZ-1治疗第2天起贯穿治疗全程)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell large granular lymphocytic leukemia (T-LGLL) is a clonal proliferation of cytotoxic T lymphocytes that can result in severe neutropenia, anemia, and bone marrow failure. Strong evidence from patients and mouse models demonstrate the critical role of interleukin-15 (IL-15) in T-LGLL pathogenesis. BNZ-1 is a pegylated peptide that selectively inhibits the binding of IL-15 and other γc cytokines to their cellular receptor complex, which has demonstrated efficacy in ex vivo T-LGLL cells and transgenic mice in preclinical studies. We conducted a phase 1/2 trial of BNZ-1 in patients with T-LGLL who had hematocytopenias (anemia or neutropenia) and required therapy. Clinical responses were assessed using hematologic parameters (improvement in hematocytopenias) based on response criteria from the Eastern Cooperative Oncology Group 5998 T-LGLL trial. BNZ-1 demonstrated clinical partial responses in 20% of patients with T-LGLL with minimal toxicity and the maximum tolerated dose was not reached. Furthermore, T-LGL leukemic cells showed significantly increased apoptosis in response to BNZ-1 treatment as early as day 2, including in clinical nonresponders, with changes that remained statistically different from baseline throughout treatment (P < .005). We report first-in-human proof that T-LGL leukemic cells are dependent on IL-15 and that intervention with IL-15 inhibition with BNZ-1 in patients with T-LGLL shows therapeutic effects, which carries important implications for the understanding of the pathogenesis of this disease. This trial was registered at www.clinicaltrials.gov as #NCT03239392.
引用
- Brammer JE, Ballen K, Sokol L, et al. Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia. Blood. 2023. PMID: 37352612. doi:10.1182/blood.2022017643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。